How to optimize hepatitis C virus treatment impact on life years saved in resource‐constrained countries

Dorothée Obach, Yazdan Yazdanpanah, Gamal Esmat, Anchalee Avihingsanon, Sahar Dewedar, Nicolas Durier, Alain Attia, Wagida A. Anwar, Anthony Cousien, Pisit Tangkijvanich, Serge Paul Eholié, Wahid Doss, Aya Mostafa, Arnaud Fontanet, Mostafa K. Mohamed, Sylvie Deuffic‐Burban – 10 January 2015 – In resource‐constrained countries where the prevalence of hepatitis C virus (HCV) disease is usually high, it is important to know which population should be treated first in order to increase treatment effectiveness.

Impaired uptake of conjugated bile acids and hepatitis b virus pres1‐binding in na+‐taurocholate cotransporting polypeptide knockout mice

Davor Slijepcevic, Christina Kaufman, Catharina G.K. Wichers, Eduardo H. Gilglioni, Florian A. Lempp, Suzanne Duijst, Dirk R. de Waart, Ronald P.J. Oude Elferink, Walter Mier, Bruno Stieger, Ulrich Beuers, Stephan Urban, Stan F.J. van de Graaf – 10 January 2015 – The Na+‐taurocholate cotransporting polypeptide (NTCP) mediates uptake of conjugated bile acids (BAs) and is localized at the basolateral membrane of hepatocytes. It has recently been recognized as the receptor mediating hepatocyte‐specific entry of hepatitis B virus and hepatitis delta virus.

Subscribe to